VIGL

Vigil Neuroscience (VIGL)

Vigil Neuroscience Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:VIGL

1 2 3 4 5 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/08	20:40	GlobeNewswire Inc.	Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	06:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	06:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	06:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	06:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	05:35	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	05:20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/08	05:05	GlobeNewswire Inc.	Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/04/18	05:05	GlobeNewswire Inc.	Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/26	20:05	GlobeNewswire Inc.	Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/20	20:05	GlobeNewswire Inc.	Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/13	20:05	GlobeNewswire Inc.	Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/12	20:05	GlobeNewswire Inc.	Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/07	06:25	GlobeNewswire Inc.	Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/02	08:08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/02	07:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/03/01	06:05	GlobeNewswire Inc.	Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/02/15	01:33	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/02/08	06:05	GlobeNewswire Inc.	Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/01/12	00:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/01/04	06:30	GlobeNewswire Inc.	Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/23	06:05	GlobeNewswire Inc.	Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/17	06:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/17	06:05	GlobeNewswire Inc.	Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/07	21:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/07	21:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/11/07	21:05	GlobeNewswire Inc.	Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/10/17	20:05	GlobeNewswire Inc.	Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/10/13	05:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2023/10/06	05:01	GlobeNewswire Inc.	Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit	NASDAQ:VIGL	Vigil Neuroscience Inc